TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06638086
Drug: Acetaminophen Suppositories
Normalized name: Acetaminophen Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per rectal suppositories
Study: NCT06638086
Drug: Acetaminophen Injection
Normalized name: acetaminophen Injection
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-venous injection
Study: NCT03817515
Drug: ABI-009
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus Albumin-bound Nanoparticles
Study: NCT05042466
Drug: Trauma
Normalized name: Traumacal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15g. thru 0.33g., M/W/F and monthly 1 time a dose of 1g. to 1.5g monthly. 8 week trial.
Study: NCT06319274
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuously infusion for 72 hours at 3 ml/hours
Study: NCT05721729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated
Study: NCT05181085
Drug: NST 6179
Normalized name: GLOVE NITRILE SM PFREE NSTERL TX
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
Study: NCT05181085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive analogue
Study: NCT04818086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which is encapsulated to look the same as the intervention drug.
Study: NCT05656274
Drug: JS1-1-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tables
Study: NCT05656274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tables
Study: NCT05269940
Drug: ZX-101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dosing, once daily
Study: NCT06015165
Drug: Analgesia plan for Anes. Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Anes. Group, hydromorphone intravenous pump (PCIA) with 0.04mg/hr and 0.2mg/hr bolus controlled administration. Rescue opioids will be given as sufentanil 5μg/hr, depending on the time of the last intraoperative administration. NSAIDs such as flurbiprofen axetil or ibuprofen will be administered as a complementary treatment option.
Study: NCT06015165
Drug: Analgesia plan for Surg. Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Surg. Group, hydromorphone intravenous pump is set with the same analgesic formula as in Anes. Group. Routine prescriptions for rescue opioids (tramadol) and NSAIDs according to pain level recommended by the pharmacy department will be administered.
Study: NCT06643247
Drug: Drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
Study: NCT06525870
Drug: 85%TCA topical application
Approvals — FDA: no, EMA: no, PMDA: no
Description: 85%TCA topical application is done at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of TCA will be applied to cover the lesion and transformation zone.
Study: NCT06525870
Drug: 3% acetic acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% acetic acid topical application is done at cervical lesion and transformation zone. Application will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of acetic acid will be applied to cover the lesion and transformation zone.
Study: NCT06500871
Drug: Diclofenac Potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NSAID
Study: NCT05782244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral, TID
Study: NCT06530303
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study: NCT04636437
Drug: Integrase strand transfer inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Study: NCT05936138
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06310824
Drug: EU-Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg dose of a single subcutaneous injection
Study: NCT06310824
Drug: US-Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg dose of a single subcutaneous injection
Study: NCT04791020
Drug: Lidocain topical + paracervical blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade
Study: NCT05156814
Drug: Femoston® 1, Femoston® 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
Study: NCT05156814
Drug: Klimadynon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifuga racemosa rhizomatum extract
Study: NCT04831619
Drug: PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
Study: NCT06480461
Drug: VGN-R09b
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
Study: NCT05262764
Drug: JARDIANCE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: JARDIANCE®
Study: NCT05003336
Drug: Xiangshao Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: dissolve 1 sachet (4 g) in water to be drank 3 times a day after meal for 8 weeks
Study: NCT05003336
Drug: Xiangshao Granules Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiangshao Granules Placebo
Study: NCT06649773
Drug: Noiiglutide Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator group
Study: NCT06011889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with placebo in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
Study: NCT06670521
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline placebo IV every 6 hours for 4 doses
Study: NCT06297213
Drug: R-2487
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-2487 DP
Study: NCT06671665
Drug: calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.
Study: NCT06671054
Drug: AP1189, 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1189 tablets for oral use
Study: NCT06671054
Drug: AP1189, 70 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1189 tablets for oral use
Study: NCT06671054
Drug: AP1189, 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1189 tablets for oral use
Study: NCT06671054
Drug: AP1189 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1189 tablets for oral use
Study: NCT06613139
Drug: YHP2305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug: YHP2305 Comparator: YHR2404
Study: NCT06613139
Drug: YHR2404
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug: YHP2305 comparator: YHR2404
Study: NCT06676085
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unfractionated heparin for anticoagulation
Study: NCT05865886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1291583
Study: NCT06675214
Drug: Full course of PD-1/PD-L1 blockades
Approvals — FDA: no, EMA: no, PMDA: no
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
Study: NCT06689852
Drug: Loceryl 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be used once a week
Study: NCT06689254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05405166
Drug: Paracetamol / Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
Study: NCT05298046
Drug: Experimental: TAVO101
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAVO101 single ascending dose IV infusion.
Study: NCT04921306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
Study: NCT05755685
Drug: Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
Study: NCT06143423
Drug: AP026 (TQA2226) for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
Study: NCT06143423
Drug: AP026 (TQA2226) for injection matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.
Study: NCT06563713
Drug: STSP-0902 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive the administration dose on Day 0 following protocol requirements
Study: NCT06563713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive the administration dose on Day 0 following protocol requirements
Study: NCT04956900
Drug: Aurase Wound gel
Normalized name: hyaluronate Topical Gel [IPM Wound]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.
Study: NCT05018598
Drug: Administration via pressurized metered dose inhaler (pMDI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5993 pMDI
Study: NCT05018598
Drug: Administration via pressurized metered dose inhaler (pMDI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF1535 pMDI or CHF5993 pMDI
Study: NCT06640504
Drug: Blood Lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The serum levels of blood lactate are divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR).
Study: NCT06642844
Drug: Avastin, 25 Mg/mL Intravenous Solution
Normalized name: Avastin, 25 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.
Study: NCT06640517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered subcutaneously at a scheme masking netakimab treatment
Study: NCT05084378
Drug: Saline Lavage Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 litre of sterile isotonic saline
Study: NCT04823052
Drug: Sulindac (HLX-0201), dose strength 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (HLX-0201) Capsule
Study: NCT04823052
Drug: Sulindac (HLX-0201), dose strength 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (HLX-0201) Capsule
Study: NCT04823052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule
Study: NCT03988439
Drug: IDP-118 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT04768478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
Study: NCT05623605
Drug: Indian costus mouth wash
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
Study: NCT05944393
Drug: Normal saline 0.9% Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided Erector Spine Plane block with 10 mL 0.9% normal saline
Study: NCT05736887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in 600mg tablets
Study: NCT06236009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching- placebo subcutaneous injections.
Study: NCT04983238
Drug: BYON5667 & SYD985
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular administration: BYON5667, Intravenous administration: SYD985
Study: NCT04983238
Drug: Placebo & SYD985
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular administration: Placebo, Intravenous administration: SYD985
Study: NCT05677126
Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralement without Manganese
Study: NCT04846868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06685679
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral melatonin 3 mg/kg/day divided in 3 doses , after enteral feeding, for 3 consecutive days, as combined therapy to milrinone
Study: NCT06682975
Drug: ZP9830
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 single dose of ZP9830 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
Study: NCT06682975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Volume will be matching the active treatment
Study: NCT06686862
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen tapering schedule during 3 weeks. First week: Ibuprofen 600 mg every 8 hours. Second week: Ibuprofen 600 mg every 12 hours. Third week: Ibuprofen 600 mg every 24 hours.
Study: NCT06690229
Drug: glass ionomer cement
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cement used for crown cementation
Study: NCT06695208
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: biodentine used in socket preservation
Study: NCT06694324
Drug: Liposomal Doxorubicin (Doxil)
Normalized name: doxorubicin hydrochloride liposome Injection [Doxil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2, d1, IV
Study: NCT06687265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one pill per os twice a day for 28 days.
Study: NCT06690476
Drug: Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration Drug：cisplatin intravenous administration Drug：paclitaxel intravenous administration In this stage, subjects will receive the treatment of IPM514 combined with Tislelizumab, cisplatin and paclitaxel. All four drugs will be administered once every 3 weeks (± 1 day). IPM514 will be administered for the first time on D0, and Tislelizumab, cisplatin and paclitaxel will be administered for the first time on D3 (the administration order: Tislelizumab - paclitaxel - cisplatin). IPM514 will be administered a total of 3 times, and PD-1 antibody, cisplatin and paclitaxel will all be administered a total of 2 times (that is, IPM514 is administered on D0/D21/D42, and Tislelizumab, paclitaxel and cisplatin are administered on D3/D24).
Study: NCT06691425
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care: mFOLFIRINOX or gemcitabine/nab-paclitaxel
Study: NCT06686030
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivgtt
Study: NCT06398054
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg tablet
Study: NCT06398054
Drug: Hyoscine N-Butil Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-Butil Bromide 10 mg two tablets
Study: NCT06538012
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study: NCT06398054
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets
Study: NCT06274047
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06496100
Drug: Placebo (calcined magnesia)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
Study: NCT05385523
Drug: dexamedatomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
Study: NCT05119335
Drug: Oral NKT2152
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIF2α inhibitor
Study: NCT06636422
Drug: Motherwort injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given motherwort injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Study: NCT06421454
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pressure Ulcer will be treated with a melatonin cream daily
Study: NCT06421454
Drug: Hydrogel
Normalized name: HYDROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure ulcer will be treated with hydrogel daily as a comparator
Study: NCT04739215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Placebo capsule daily oral
Study: NCT06637384
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals, Pakistan
Study: NCT06357377
Drug: NEO100
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol.~NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol.
Study: NCT06643780
Drug: Zolendronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
Study: NCT06643130
Drug: JW0104+C2402
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 8 weeks(PO (Per Oral), QD)
Study: NCT06643130
Drug: JW0104+C2403
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 8 weeks(PO, QD)
Study: NCT05804084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar capsule manufactured to match encapsulated Acetazolamide
Study: NCT05682443
Drug: ONC-392
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC-392 will be given as IV infusion, Q6W, for up to 9 doses.
Study: NCT05682443
Drug: lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses.
Approvals — FDA: no, EMA: no, PMDA: no
Description: lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.
Study: NCT06475495
Drug: KYV101
Approvals — FDA: no, EMA: no, PMDA: no
Description: an autologous fully-human anti-CD19 CAR T-cell immunotherapy
Study: NCT06304896
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg oral tablets. Prescribed: Once daily PO with 200 mL of water.
Study: NCT06304896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules. Prescribed: Once daily PO with 200 mL of water.
Study: NCT05812300
Drug: Freshly manufactured 35 kDa hyaluronan fragment
Normalized name: PALMITOYL FRAGMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
Study: NCT05540184
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
Study: NCT05745883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered subcutaneously
Study: NCT06054815
Drug: DA-1241 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of Administration: Oral, with subjects in a fasting state
Study: NCT06541249
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.
Study: NCT05025605
Drug: BXCL501 80 Micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual film containing 80 Micrograms BXCL501